Overview
- Cristiano Ronaldo purchased a 10% equity stake in Herbalife’s personalized health-tech unit, HBL Pro2col, for $7.5 million and agreed to provide services and sponsorship rights to the subsidiary.
- HBL Pro2col is a software platform that uses user inputs, wearable-device data and DNA analysis to deliver individualized nutrition and wellness recommendations.
- Herbalife paired the announcement with Q4 2025 results, posting adjusted EPS of $0.45 versus a $0.43 estimate and revenue of about $1.3 billion versus a $1.25 billion forecast.
- Q4 sales rose 6.3% year over year and full-year 2025 sales increased 1%, which, alongside the Ronaldo deal, helped send HLF up about 18% Thursday and to a new 52-week high.
- Ronaldo has been a Herbalife partner since 2013, but this is his first disclosed investment in the firm, and despite the surge, Wall Street’s Moderate Buy consensus carries an average price target implying roughly 20% downside from current levels.